This requires Flash to play. Click here to download.

Visible Improvements in CTCL With ZOLINZA

Choose 1 of 4 patient responses from a clinical trial with ZOLINZA. View patient responses at baseline, week 21 and week 53.
Patient 1 stage at baseline: IVB sézary syndrome
Patient 2 stage at baseline: IIB mycosis fungoides
Patient 3 stage at baseline: IVA mycosis fungoides
Patient 4 stage at baseline: IVA sézary syndrome
*Sample responses during treatment with ZOLINZA for sézary syndrome and mycosis fungoides: In the pivotal trial, 30% (22/74, 95% CI [19.7% to 41.5%]) of patients experienced an objective response.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety profile Dosage Reimbursement Resource center CTCL overview Prescribing Information Patient Information
Patient Product Information

Visible improvements in CTCL
with ZOLINZAa

This requires Flash to play. Click here to download.

Visible Improvements in CTCL With ZOLINZA

Choose 1 of 4 patient responses from a clinical trial with ZOLINZA. View patient responses at baseline, week 21 and week 53.
Patient 1 stage at baseline: IVB sézary syndrome
Patient 2 stage at baseline: IIB mycosis fungoides
Patient 3 stage at baseline: IVA mycosis fungoides
Patient 4 stage at baseline: IVA sézary syndrome
*Sample responses during treatment with ZOLINZA for sézary syndrome and mycosis fungoides: In the pivotal trial, 30% (22/74, 95% CI [19.7% to 41.5%]) of patients experienced an objective response.

  • Cutaneous T-cell lymphomas are a heterogeneous group of cutaneous non-Hodgkin’s lymphomas,1 the 2 most common forms of which are mycosis fungoides (MF) and Sézary syndrome (SS).
Reference: 1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.

Study design

Open-label, single-agent, multicenter trial in patients (N=74) treated with ZOLINZA 400 mg once daily. Patients studied were aged 39 to 83 years (median 60 years); 48.6% female and 51.4% male; 82.4% white, 14.9% black, 1.4% Asian, and 1.4% other.

Objective response (primary end point)=either complete clinical response (CCR), defined as no evidence of disease, or partial response (PR), defined as a ≥50% decrease in SWAT skin assessment score compared with baseline. Both CCR and PR had to be maintained for at least 4 weeks.

Selected Important Safety Information

  • QTc prolongation has been observed. Monitor electrolytes and ECGs at baseline and periodically during treatment. Administer with caution in patients who have or may develop QTc prolongation. Hypokalemia or hypomagnesemia should be corrected before administering ZOLINZA.

Before prescribing ZOLINZA, please read the physician Prescribing Information. The Patient Information also is available.

Back to top


Home | Patient Information | Prescribing Information
ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20852912(1)-02/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.